The price of Immunome Inc (NASDAQ: IMNM) closed at $18.85 in the last session, down -8.41% from day before closing price of $20.58. On the day, 718056 shares were traded.
Ratios:
We take a closer look at IMNM’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.63 and its Current Ratio is at 6.63. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on April 15, 2024, initiated with a Buy rating and assigned the stock a target price of $35.
On January 29, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $30.
On December 19, 2023, Wedbush started tracking the stock assigning a Outperform rating and target price of $12.Wedbush initiated its Outperform rating on December 19, 2023, with a $12 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 02 ’23 when SIEGALL CLAY B bought 169,204 shares for $5.91 per share. The transaction valued at 999,996 led to the insider holds 319,636 shares of the business.
Turner Bruce bought 42,300 shares of IMNM for $249,993 on Oct 02 ’23. The Chief Strategy Officer now owns 42,300 shares after completing the transaction at $5.91 per share.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 80.25 while its Price-to-Book (P/B) ratio in mrq is 6.80.
Stock Price History:
Over the past 52 weeks, IMNM has reached a high of $30.96, while it has fallen to a 52-week low of $4.44.
Shares Statistics:
A total of 59.69M shares are outstanding, with a floating share count of 48.31M. Insiders hold about 19.07% of the company’s shares, while institutions hold 35.83% stake in the company.
Earnings Estimates
The company has MNM analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $18.85, with high estimates of $0.65 and low estimates of $1.47.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare.
